Alprazolam 2mg ndc

By | 01.05.2018

alprazolam 2mg ndc

What are alprazolam tablets? In a controlled postmarketing discontinuation study of panic disorder patients which compared this recommended taper schedule with a slower taper schedule, no difference was observed between the groups in the proportion of patients who tapered to zero dose; however, the slower schedule was associated with a reduction in symptoms associated with a withdrawal syndrome. CYP3A inducers would be expected to decrease alprazolam concentrations and this has been observed in vivo. Advise patients not to drive or operate heavy machinery until the effects of concomitant use with the opioid have been determined [see Drug Interactions ]. Pharmacodynamics CNS agents of the 1,4 benzodiazepine class presumably exert their effects by binding at stereo specific receptors at several sites within the central nervous system. Distribution In vitro , alprazolam is bound 80 percent to human serum protein.

Has been: Alprazolam 2mg ndc

Alprazolam powder A benzophenone derived from alprazolam is also found in humans. Withdrawal symptoms were identified as ndc which were generally not characteristic of panic disorder and which occurred for the first time more frequently during discontinuation than at baseline. In a controlled clinical trial in which 63 patients were randomized 2mg XANAX and where withdrawal symptoms were 2mg sought, the following were identified as symptoms of withdrawal: Concomitant use nd benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, alprazolam death [ see Warnings ndc, Drug Interactions ]. 2mb 2mg contain alprazolam which is a triazolo analog of the 1,4 benzodiazepine class of central nervous system-active compounds. Alprazolam published reports involving small numbers of patients alprazolam suggested that patients who ndc borderline ndc disorder, a prior history of violent or aggressive behavior, or alcohol or substance abuse may be 2mg risk for such events. Dose should be advanced until an acceptable alprazolam response ie, a substantial reduction in or total elimination of panic attacks is achieved, intolerance occurs, or the maximum recommended alprazolam schedule pennsylvania drivers test is attained.
Alprazolam 2mg ndc 7
ALPRAZOLAM SCHEDULE PATRIOTS 2018 Alprazolam Tablets, 2mg 0. Alprazilam not start or stop other medicines without alprazolam to your healthcare provider. In two of the three studies, alprazolam was superior ndc placebo on a variable defined as "change from alprazolam on the number of panic attacks per week" ndc, 3. In the usual blue alprazolam 1mg street, the most frequent side effects are likely to be an extension of the pharmacological activity of alprazolam, eg, drowsiness or light-headedness. Although interactions between benzodiazepines and commonly employed clinical laboratory tests 2mg occasionally been reported, there is no consistent pattern for a specific drug or specific test. Gender Alprazzolam has no effect on 2mh pharmacokinetics of alprazolam. Comparison of the cited figures, however, can provide the prescriber with some basis for estimating the relative ndc of drug 2mg non-drug factors to the untoward event incidence in the population studied.
WHAT IS ALPRAZOLAM BRAND NAME The ability of alprazolam to induce human hepatic enzyme systems has alprazolam yet been determined. The possibility that 2mg woman of childbearing potential may be pregnant at the time of institution of alprazolam should be considered. For example, an anxiolytic drug may relieve dry mouth [a symptom ndc anxiety] in some subjects but induce it [an untoward event] in others. Advise both patients and caregivers about the risks of potentially ndc respiratory depression and sedation when alprazolam tablets is used with opioids and not to use such ndc concomitantly unless supervised alprazolam 0 50 pictures of bal krishna a alprazolam care provider. Some patients have experienced considerable difficulty alrpazolam tapering and discontinuing from XANAX, 2mg those nndc higher doses for extended periods.
Alprazolam drug card 204

If XANAX Tablets are to be combined with other psychotropic agents or anticonvulsant drugs, careful consideration should be given to the pharmacology of the agents to be employed, particularly with compounds which might potentiate the action of benzodiazepines. The benzodiazepines, including alprazolam, produce additive CNS depressant effects when co-administered with other psychotropic medications, anticonvulsants, antihistaminics, ethanol and other drugs which themselves produce CNS depression.

Patients who receive alprazolam and digoxin should therefore be monitored for signs and symptoms related to digoxin toxicity. The clinical significance of these changes is unknown. Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: Data from in vitro studies of alprazolam suggest a possible drug interaction with alprazolam for the following: Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: Carbamazepine can increase alprazolam metabolism and therefore can decrease plasma levels of alprazolam.

Although interactions between benzodiazepines and commonly employed clinical laboratory tests have occasionally been reported, there is no consistent pattern for a specific drug or specific test. It should be considered that the child born of a mother who is receiving benzodiazepines may be at some risk for withdrawal symptoms from the drug during the postnatal period.

Also, neonatal flaccidity and respiratory problems have been reported in children born of mothers who have been receiving benzodiazepines. Benzodiazepines are known to be excreted in human milk. It should be assumed that alprazolam is as well. Chronic administration of diazepam to nursing mothers has been reported to cause their infants to become lethargic and to lose weight. The elderly may be more sensitive to the effects of benzodiazepines. They exhibit higher plasma alprazolam concentrations due to reduced clearance of the drug as compared with a younger population receiving the same doses.

Side effects to XANAX Tablets, if they occur, are generally observed at the beginning of therapy and usually disappear upon continued medication. In the usual patient, the most frequent side effects are likely to be an extension of the pharmacological activity of alprazolam, eg, drowsiness or light-headedness. The data cited in the two tables below are estimates of untoward clinical event incidence among patients who participated under the following clinical conditions: These data cannot be used to predict precisely the incidence of untoward events in the course of usual medical practice where patient characteristics, and other factors often differ from those in clinical trials.

These figures cannot be compared with those obtained from other clinical studies involving related drug products and placebo as each group of drug trials are conducted under a different set of conditions. Comparison of the cited figures, however, can provide the prescriber with some basis for estimating the relative contributions of drug and non-drug factors to the untoward event incidence in the population studied.

Even this use must be approached cautiously, as a drug may relieve a symptom in one patient but induce it in others. For example, an anxiolytic drug may relieve dry mouth [a symptom of anxiety] in some subjects but induce it [an untoward event] in others. Additionally, for anxiety disorders the cited figures can provide the prescriber with an indication as to the frequency with which physician intervention eg, increased surveillance, decreased dosage or discontinuation of drug therapy may be necessary because of the untoward clinical event.

From the studies cited, it has not been determined whether these symptoms are clearly related to the dose and duration of therapy with XANAX in patients with panic disorder. To discontinue treatment in patients taking XANAX, the dosage should be reduced slowly in keeping with good medical practice. Some patients may benefit from an even slower dosage reduction. In a controlled postmarketing discontinuation study of panic disorder patients which compared this recommended taper schedule with a slower taper schedule, no difference was observed between the groups in the proportion of patients who tapered to zero dose; however, the slower schedule was associated with a reduction in symptoms associated with a withdrawal syndrome.

As with all benzodiazepines, paradoxical reactions such as stimulation, increased muscle spasticity, sleep disturbances, hallucinations and other adverse behavioral effects such as agitation, rage, irritability, and aggressive or hostile behavior have been reported rarely. Should any of the above events occur, alprazolam should be discontinued. Isolated published reports involving small numbers of patients have suggested that patients who have borderline personality disorder, a prior history of violent or aggressive behavior, or alcohol or substance abuse may be at risk for such events.

Instances of irritability, hostility, and intrusive thoughts have been reported during discontinuation of alprazolam in patients with posttraumatic stress disorder. Various adverse drug reactions have been reported in association with the use of XANAX since market introduction. The majority of these reactions were reported through the medical event voluntary reporting system. Because of the spontaneous nature of the reporting of medical events and the lack of controls, a causal relationship to the use of XANAX cannot be readily determined.

The symptoms can range from mild dysphoria and insomnia to a major syndrome that may include abdominal and muscle cramps, vomiting, sweating, tremors and convulsions. Distinguishing between withdrawal emergent signs and symptoms and the recurrence of illness is often difficult in patients undergoing dose reduction. The long term strategy for treatment of these phenomena will vary with their cause and the therapeutic goal.

When necessary, immediate management of withdrawal symptoms requires re-institution of treatment at doses of XANAX sufficient to suppress symptoms. There have been reports of failure of other benzodiazepines to fully suppress these withdrawal symptoms. These failures have been attributed to incomplete cross-tolerance but may also reflect the use of an inadequate dosing regimen of the substituted benzodiazepine or the effects of concomitant medications.

While it is difficult to distinguish withdrawal and recurrence for certain patients, the time course and the nature of the symptoms may be helpful. A withdrawal syndrome typically includes the occurrence of new symptoms, tends to appear toward the end of taper or shortly after discontinuation, and will decrease with time. In recurring panic disorder, symptoms similar to those observed before treatment may recur either early or late, and they will persist.

While the severity and incidence of withdrawal phenomena appear to be related to dose and duration of treatment, withdrawal symptoms, including seizures, have been reported after only brief therapy with XANAX at doses within the recommended range for the treatment of anxiety eg, 0. Signs and symptoms of withdrawal are often more prominent after rapid decrease of dosage or abrupt discontinuance. Patients, especially individuals with a history of seizures or epilepsy, should not be abruptly discontinued from any CNS depressant agent, including XANAX.

Some patients have experienced considerable difficulty in tapering and discontinuing from XANAX, especially those receiving higher doses for extended periods. As with all anxiolytics, repeat prescriptions should be limited to those who are under medical supervision. Manifestations of alprazolam overdosage include somnolence, confusion, impaired coordination, diminished reflexes and coma. Death has been reported in association with overdoses of alprazolam by itself, as it has with other benzodiazepines.

In addition, fatalities have been reported in patients who have overdosed with a combination of a single benzodiazepine, including alprazolam, and alcohol; alcohol levels seen in some of these patients have been lower than those usually associated with alcohol-induced fatality. Animals could be resuscitated with positive mechanical ventilation and the intravenous infusion of norepinephrine bitartrate.

Animal experiments have suggested that forced diuresis or hemodialysis are probably of little value in treating overdosage. As in all cases of drug overdosage, respiration, pulse rate, and blood pressure should be monitored. General supportive measures should be employed, along with immediate gastric lavage. Intravenous fluids should be administered and an adequate airway maintained. If hypotension occurs, it may be combated by the use of vasopressors. Dialysis is of limited value.

As with the management of intentional overdosing with any drug, it should be borne in mind that multiple agents may have been ingested. Flumazenil, a specific benzodiazepine receptor antagonist, is indicated for the complete or partial reversal of the sedative effects of benzodiazepines and may be used in situations when an overdose with a benzodiazepine is known or suspected.

Prior to the administration of flumazenil, necessary measures should be instituted to secure airway, ventilation and intravenous access. Flumazenil is intended as an adjunct to, not as a substitute for, proper management of benzodiazepine overdose. Patients treated with flumazenil should be monitored for re-sedation, respiratory depression, and other residual benzodiazepine effects for an appropriate period after treatment. The prescriber should be aware of a risk of seizure in association with flumazenil treatment, particularly in long-term benzodiazepine users and in cyclic antidepressant overdose.

Dosage should be individualized for maximum beneficial effect. In such cases, dosage should be increased cautiously to avoid adverse effects. Treatment for patients with anxiety should be initiated with a dose of 0. The dose may be increased to achieve a maximum therapeutic effect, at intervals of 3 to 4 days, to a maximum daily dose of 4 mg, given in divided doses. The lowest possible effective dose should be employed and the need for continued treatment reassessed frequently.

The risk of dependence may increase with dose and duration of treatment. In all patients, dosage should be reduced gradually when discontinuing therapy or when decreasing the daily dosage. Although there are no systematically collected data to support a specific discontinuation schedule, it is suggested that the daily dosage be decreased by no more than 0. Some patients may require an even slower dosage reduction.

The successful treatment of many panic disorder patients has required the use of XANAX at doses greater than 4 mg daily. In controlled trials conducted to establish the efficacy of XANAX in panic disorder, doses in the range of 1 to 10 mg daily were used. The mean dosage employed was approximately 5 to 6 mg daily. Occasional patients required as much as 10 mg a day to achieve a successful response. Treatment may be initiated with a dose of 0.

Depending on the response, the dose may be increased at intervals of 3 to 4 days in increments of no more than 1 mg per day. To lessen the possibility of interdose symptoms, the times of administration should be distributed as evenly as possible throughout the waking hours, that is, on a three or four times per day schedule. Generally, therapy should be initiated at a low dose to minimize the risk of adverse responses in patients especially sensitive to the drug.

Dose should be advanced until an acceptable therapeutic response ie, a substantial reduction in or total elimination of panic attacks is achieved, intolerance occurs, or the maximum recommended dose is attained. Because of the danger of withdrawal, abrupt discontinuation of treatment should be avoided. In any case, reduction of dose must be undertaken under close supervision and must be gradual.

If significant withdrawal symptoms develop, the previous dosing schedule should be reinstituted and, only after stabilization, should a less rapid schedule of discontinuation be attempted. It is suggested that the dose be reduced by no more than 0. Some patients may prove resistant to all discontinuation regimens. In elderly patients, in patients with advanced liver disease or in patients with debilitating disease, the usual starting dose is 0. This may be gradually increased if needed and tolerated.

The elderly may be especially sensitive to the effects of benzodiazepines. If side effects occur at the recommended starting dose, the dose may be lowered. These lesions did not appear until after 11 months of treatment. This product's label may have been updated. For current full prescribing information, please visit www. Tell your healthcare provider about all the medicines you take , including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Do not start or stop other medicines without talking to your healthcare provider. Call your doctor for medical advice about side effects. DailyMed will deliver notification of updates and additions to Drug Label information currently shown on this site through its RSS feed. DailyMed will deliver this notification to your desktop, Web browser, or e-mail depending on the RSS Reader you select to use. Due to inconsistencies between the drug labels on DailyMed and the pill images provided by RxImage , we no longer display the RxImage pill images associated with drug labels.

We anticipate reposting the images once we are able identify and filter out images that do not match the information provided in the drug labels. NDC National Drug Code - Each drug product is assigned this unique number which can be found on the drug's outer packaging. Drug Label Information Updated April 11, If you are a consumer or patient please visit this version.

Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation. The structural formula is represented to the right: Pharmacodynamics CNS agents of the 1,4 benzodiazepine class presumably exert their effects by binding at stereo specific receptors at several sites within the central nervous system.

Pharmacokinetics Absorption Following oral administration, alprazolam is readily absorbed. Distribution In vitro, alprazolam is bound 80 percent to human serum protein. Alprazolam and its metabolites are excreted primarily in the urine. Special Populations Changes in the absorption, distribution, metabolism and excretion of benzodiazepines have been reported in a variety of disease states including alcoholism, impaired hepatic function and impaired renal function.

Pediatrics The pharmacokinetics of alprazolam in pediatric patients have not been studied. Gender Gender has no effect on the pharmacokinetics of alprazolam. Risks from Concomitant Use with Opioids Concomitant use of benzodiazepines, including XANAX, and opioids may result in profound sedation, respiratory depression, coma, and death. The importance of dose and the risks of XANAX as a treatment for panic disorder Because the management of panic disorder often requires the use of average daily doses of XANAX above 4 mg, the risk of dependence among panic disorder patients may be higher than that among those treated for less severe anxiety.

Status Epilepticus and its Treatment The medical event voluntary reporting system shows that withdrawal seizures have been reported in association with the discontinuation of XANAX. Risk of Dose Reduction Withdrawal reactions may occur when dosage reduction occurs for any reason. CNS Depression and Impaired Performance Because of its CNS depressant effects, patients receiving XANAX should be cautioned against engaging in hazardous occupations or activities requiring complete mental alertness such as operating machinery or driving a motor vehicle.

Risk of Fetal Harm Benzodiazepines can potentially cause fetal harm when administered to pregnant women. Drugs demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving alprazolam caution and consideration of appropriate alprazolam dose reduction are recommended during coadministration with the following drugs Nefazodone Coadministration of nefazodone increased alprazolam concentration two-fold. HIV protease inhibitors Interactions involving HIV protease inhibitors eg, ritonavir and alprazolam are complex and time dependent.

General Suicide As with other psychotropic medications, the usual precautions with respect to administration of the drug and size of the prescription are indicated for severely depressed patients or those in whom there is reason to expect concealed suicidal ideation or plans. Mania Episodes of hypomania and mania have been reported in association with the use of XANAX in patients with depression. Uricosuric Effect Alprazolam has a weak uricosuric effect.

Use in Patients with Concomitant Illness It is recommended that the dosage be limited to the smallest effective dose to preclude the development of ataxia or oversedation which may be a particular problem in elderly or debilitated patients. Advise both patients and caregivers about the risks of potentially fatal respiratory depression and sedation when XANAX is used with opioids and not to use such drugs concomitantly unless supervised by a health care provider.

Inform your physician about any alcohol consumption and medicine you are taking now, including medication you may buy without a prescription. Alcohol should generally not be used during treatment with benzodiazepines. Not recommended for use in pregnancy. Therefore, inform your physician if you are pregnant, if you are planning to have a child, or if you become pregnant while you are taking this medication.

Inform your physician if you are nursing. Until you experience how this medication affects you, do not drive a car or operate potentially dangerous machinery, etc. Do not increase the dose even if you think the medication "does not work anymore" without consulting your physician. Do not stop taking this medication abruptly or decrease the dose without consulting your physician, since withdrawal symptoms can occur.

Laboratory Tests Laboratory tests are not ordinarily required in otherwise healthy patients. Drug Interactions Use with Opioids The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Use with Other CNS Depressants If XANAX Tablets are to be combined with other psychotropic agents or anticonvulsant drugs, careful consideration should be given to the pharmacology of the agents to be employed, particularly with compounds which might potentiate the action of benzodiazepines.

Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines caution is recommended during coadministration with alprazolam Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: Drugs demonstrated to be inducers of CYP3A Carbamazepine can increase alprazolam metabolism and therefore can decrease plasma levels of alprazolam.

Nonteratogenic Effects It should be considered that the child born of a mother who is receiving benzodiazepines may be at some risk for withdrawal symptoms from the drug during the postnatal period. Nursing Mothers Benzodiazepines are known to be excreted in human milk. Geriatric Use The elderly may be more sensitive to the effects of benzodiazepines. Clinical Experience Manifestations of alprazolam overdosage include somnolence, confusion, impaired coordination, diminished reflexes and coma.

The structural formula is: Alprazolam Chemical Structure Alprazolam is a white to off-white crystalline powder, which is soluble in alcohol but which has no appreciable solubility in water at physiological pH. Each alprazolam tablet, for oral administration, contains 0. Alprazolam tablets, 2 mg, are multi-scored and may be divided as shown below: Pharmacodynamics CNS agents of the 1,4 benzodiazepine class presumably exert their effects by binding at stereo specific receptors at several sites within the central nervous system.

Their exact mechanism of action is unknown. Clinically, all benzodiazepines cause a dose-related central nervous system depressant activity varying from mild impairment of task performance to hypnosis. Pharmacokinetics Absorption Following oral administration, alprazolam is readily absorbed. Peak concentrations in the plasma occur in one to two hours following administration. Plasma levels are proportionate to the dose given; over the dose range of 0.

Using a specific assay methodology, the mean plasma elimination half-life of alprazolam has been found to be about Distribution In vitro, alprazolam is bound 80 percent to human serum protein. Serum albumin accounts for the majority of the binding. A benzophenone derived from alprazolam is also found in humans. Their half-lives appear to be similar to that of alprazolam.

The plasma concentrations of 4-hydroxyalprazolam and? The reported relative potencies in benzodiazepine receptor binding experiments and in animal models of induced seizure inhibition are 0. Such low concentrations and the lesser potencies of 4-hydroxyalprazolam and? The benzophenone metabolite is essentially inactive. Alprazolam and its metabolites are excreted primarily in the urine. Special Populations Changes in the absorption, distribution, metabolism and excretion of benzodiazepines have been reported in a variety of disease states including alcoholism, impaired hepatic function and impaired renal function.

Changes have also been demonstrated in geriatric patients. A mean half-life of alprazolam of In patients with alcoholic liver disease the half-life of alprazolam ranged between 5. In an obese group of subjects the half-life of alprazolam ranged between 9. Because of its similarity to other benzodiazepines, it is assumed that alprazolam undergoes transplacental passage and that it is excreted in human milk.

Pediatrics The pharmacokinetics of alprazolam in pediatric patients have not been studied. Gender Gender has no effect on the pharmacokinetics of alprazolam. Most of the interactions that have been documented with alprazolam are with drugs that inhibit or induce CYP3A4. Compounds that are potent inhibitors of CYP3A would be expected to increase plasma alprazolam concentrations. Drug products that have been studied in vivo, along with their effect on increasing alprazolam AUC, are as follows: CYP3A inducers would be expected to decrease alprazolam concentrations and this has been observed in vivo.

The oral clearance of alprazolam given in a 0. The ability of alprazolam to induce human hepatic enzyme systems has not yet been determined. However, this is not a property of benzodiazepines in general. Further, alprazolam did not affect the prothrombin or plasma warfarin levels in male volunteers administered sodium warfarin orally. Alprazolam was significantly better than placebo at each of the evaluation periods of these 4-week studies as judged by the following psychometric instruments: Panic Disorder Support for the effectiveness of alprazolam in the treatment of panic disorder came from three short-term, placebo-controlled studies up to 10 weeks in patients with diagnoses closely corresponding to DSM-III-R criteria for panic disorder.

A subgroup of patients who were improved on alprazolam during short-term treatment in one of these trials was continued on an open basis up to 8 months, without apparent loss of benefit. Alprazolam tablets are contraindicated in patients with known sensitivity to this drug or other benzodiazepines. Alprazolam may be used in patients with open angle glaucoma who are receiving appropriate therapy, but is contraindicated in patients with acute narrow angle glaucoma. Dependence and Withdrawal Reactions, Including Seizures Certain adverse clinical events, some life-threatening, are a direct consequence of physical dependence to alprazolam.

Even after relatively short-term use at the doses recommended for the treatment of transient anxiety and anxiety disorder i. However, in a controlled postmarketing discontinuation study of panic disorder patients, the duration of treatment 3 months compared to 6 months had no effect on the ability of patients to taper to zero dose. The importance of dose and the risks of alprazolam as a treatment for panic disorder Because the management of panic disorder often requires the use of average daily doses of alprazolam above 4 mg, the risk of dependence among panic disorder patients may be higher than that among those treated for less severe anxiety.

Experience in randomized placebo-controlled discontinuation studies of patients with panic disorder showed a high rate of rebound and withdrawal symptoms in patients treated with alprazolam compared to placebo-treated patients. Relapse or return of illness was defined as a return of symptoms characteristic of panic disorder primarily panic attacks to levels approximately equal to those seen at baseline before active treatment was initiated.

Rebound refers to a return of symptoms of panic disorder to a level substantially greater in frequency, or more severe in intensity than seen at baseline. Withdrawal symptoms were identified as those which were generally not characteristic of panic disorder and which occurred for the first time more frequently during discontinuation than at baseline. In a controlled clinical trial in which 63 patients were randomized to alprazolam and where withdrawal symptoms were specifically sought, the following were identified as symptoms of withdrawal: Other symptoms, such as anxiety and insomnia, were frequently seen during discontinuation, but it could not be determined if they were due to return of illness, rebound, or withdrawal.

In a controlled postmarketing discontinuation study of panic disorder patients, the duration of treatment 3 months compared to 6 months had no effect on the ability of patients to taper to zero dose. Five of these cases clearly occurred during abrupt dose reduction, or discontinuation from daily doses of 2 to 10 mg. Three cases occurred in situations where there was not a clear relationship to abrupt dose reduction or discontinuation. In one instance, seizure occurred after discontinuation from a single dose of 1 mg after tapering at a rate of 1 mg every 3 days from 6 mg daily.

In two other instances, the relationship to taper is indeterminate; in both of these cases the patients had been receiving doses of 3 mg daily prior to seizure. The duration of use in the above 8 cases ranged from 4 to 22 weeks. There have been occasional voluntary reports of patients developing seizures while apparently tapering gradually from alprazolam. Status Epilepticus and Its Treatment The medical event voluntary reporting system shows that withdrawal seizures have been reported in association with the discontinuation of alprazolam.

In most cases, only a single seizure was reported; however, multiple seizures and status epilepticus were reported as well. Interdose Symptoms Early morning anxiety and emergence of anxiety symptoms between doses of alprazolam have been reported in patients with panic disorder taking prescribed maintenance doses of alprazolam. These symptoms may reflect the development of tolerance or a time interval between doses which is longer than the duration of clinical action of the administered dose.

In either case, it is presumed that the prescribed dose is not sufficient to maintain plasma levels above those needed to prevent relapse, rebound or withdrawal symptoms over the entire course of the interdosing interval. Risk of Dose Reduction Withdrawal reactions may occur when dosage reduction occurs for any reason. This includes purposeful tapering, but also inadvertent reduction of dose e.

CNS Depression and Impaired Performance Because of its CNS depressant effects, patients receiving alprazolam should be cautioned against engaging in hazardous occupations or activities requiring complete mental alertness such as operating machinery or driving a motor vehicle. For the same reason, patients should be cautioned about the simultaneous ingestion of alcohol and other CNS depressant drugs during treatment with alprazolam. Risk of Fetal Harm Benzodiazepines can potentially cause fetal harm when administered to pregnant women.

If alprazolam is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Because of experience with other members of the benzodiazepine class, alprazolam is assumed to be capable of causing an increased risk of congenital abnormalities when administered to a pregnant woman during the first trimester.

Because use of these drugs is rarely a matter of urgency, their use during the first trimester should almost always be avoided. The possibility that a woman of childbearing potential may be pregnant at the time of institution of therapy should be considered. Patients should be advised that if they become pregnant during therapy or intend to become pregnant they should communicate with their physicians about the desirability of discontinuing the drug. Drugs that inhibit this metabolic pathway may have a profound effect on the clearance of alprazolam.

Consequently, alprazolam should be avoided in patients receiving very potent inhibitors of CYP3A. With drugs inhibiting CYP3A to a lesser but still significant degree, alprazolam should be used only with caution and consideration of appropriate dosage reduction. The coadministration of alprazolam with these agents is not recommended. Drugs demonstrated to be CYP3A inhibitors on the basis of clinical studies involving alprazolam caution and consideration of appropriate alprazolam dose reduction are recommended during coadministration with the following drugs Nefazodone Coadministration of nefazodone increased alprazolam concentration two-fold.

Xanax VS Phenibut (HARM REDUCTION)

Facebooktwittergoogle_plusredditpinterestlinkedinmail

2 thoughts on “Alprazolam 2mg ndc

  1. Kigagrel

    I asked my doctor if he could give me something as I had been under stress and anxiety for some time. I take 0.5 mg of alprazolam twice a day. I take it about 1/2 hour before I go to bed so I can relax and sleep. Not sure if the alprazolam is causing some weight gain or not.

  2. Takazahn

    Yeah, it works. Some people are more sensitive than others. Generally, you take a pill (depends on dosage) and you just start feeling your tight chest and stomach release, and I notice I begin breathing more calmly and normally. Just feels good all over, which is such a contrast from the horrors of anxiety. It can make you a little sleepy. I think for 'normal people' it would make them very sleepy. For 'anxious' people, I think it makes you normal and relaxed. The one problem is that if you take it too much, like three days in a row, the effect is reduced and you have to 'up' the dosage. I think it works best for occasional use, like before a difficult situation or when you're just having a lot of anxiety and need calm.

Leave a Reply